Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis

Languages

Service navigation

Search

Contact information

Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis

The biopharmaceutical infliximab is a monoclonal antibody (mAb) used to treat a number of inflammatory autoimmune diseases including rheumatoid arthritis (RA). In 2019, infliximab generated costs of around CHF 132 million, rendering it the second most cost-incurring drug reimbursed by the mandatory health insurance in Switzerland.
Some European countries adopted policies recommending the substitution of infliximab reference products with biosimilars like initiating treatment with infliximab biosimilars as well as switching patients from infliximab reference product to biosimilars. In Switzerland, the legal framework does not facilitate implementing similar policies.
The aim of the HTA is to evaluate the efficacy, safety, cost-effectiveness and budgetary impact of initiating treatment with infliximab biosimilars as well as of switching patients from infliximab reference product to biosimilars in rheumatoid arthritis patients.

Dokumente

HTA report (PDF, 3 MB, 17.08.2021)

Scoping report (PDF, 1 MB, 02.10.2020)

Stakeholder feedback on the scoping report (PDF, 493 kB, 02.10.2020)

< back to HTA projects

Last modification 17.08.2021

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/infliximab.html